...I'm Charles Duncan. I'm a biotech analyst with Cantor, and it's a pleasure to introduce the next presenting company, ACADIA Pharmaceuticals for the Cantor Global Healthcare Conference in 2023. ACADIA is a company that I have covered for a long time, about a decade or more, and know it quite well. It's an interesting, what I consider, neuro innovator, which has long had a drug for the treatment, the only drug that's approved for the treatment of psychosis associated with Parkinson's disease. But it has seen a very interesting, I think interesting, evolution in its business with the approval of the first drug ever for the rare developmental neurological disease called the Rett syndrome. And so it's a pleasure to introduce Mark Schneyer, the company's Chief Financial Officer. Mark, thank you for joining. Mark C. Schneyer ...
